Michael Kragh Selected Research

Squamous Cell Carcinoma of Head and Neck

1/2016

Targeting the HER Family with Pan-HER Effectively Overcomes Resistance to Cetuximab.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Michael Kragh Research Topics

Disease

31	Neoplasms (Cancer) 01/2020 - 02/2002
8	Colorectal Neoplasms (Colorectal Cancer) 01/2020 - 10/2013
3	Stomach Neoplasms (Stomach Cancer) 11/2019 - 01/2018
3	Neoplasm Metastasis (Metastasis) 02/2016 - 07/2005
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2020 - 12/2013
2	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 01/2016 - 10/2013
2	Renal Cell Carcinoma (Grawitz Tumor) 03/2008 - 09/2007
1	Body Weight (Weight, Body) 01/2020
1	Residual Neoplasm 01/2020
1	Triple Negative Breast Neoplasms 01/2020
1	Glioblastoma (Glioblastoma Multiforme) 07/2018
1	Carcinogenesis 02/2016
1	Squamous Cell Carcinoma of Head and Neck 01/2016
1	Squamous Cell Carcinoma (Epidermoid Carcinoma) 01/2016
1	Breast Neoplasms (Breast Cancer) 03/2015
1	Lung Neoplasms (Lung Cancer) 12/2013
1	Melanoma (Melanoma, Malignant) 03/2008
1	Experimental Melanoma 09/2007
1	Hemorrhage 10/2005
1	Embolism (Embolus) 10/2005
1	Foreign-Body Reaction 02/2003
1	Carcinoma (Carcinomatosis) 05/2002
1	Glioma (Gliomas) 02/2002

Drug/Important Bio-Agent (IBA)

13	ErbB Receptors (EGF Receptor)IBA 01/2020 - 01/2010
10	futuximabIBA 01/2020 - 01/2010
7	AntibodiesIBA 01/2020 - 01/2010
6	LigandsIBA 01/2020 - 01/2010
6	Monoclonal AntibodiesIBA 04/2018 - 09/2007
6	Cetuximab (Erbitux)FDA Link 01/2016 - 10/2013
5	Proteins (Proteins, Gene)FDA Link 01/2020 - 09/2007
4	EpitopesIBA 12/2017 - 01/2010
3	Trastuzumab (Herceptin)FDA Link 11/2019 - 03/2015
3	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2018 - 01/2016
3	Panitumumab (Vectibix)FDA Link 01/2016 - 06/2015
2	emibetuzumabIBA 01/2018 - 10/2017
2	CytokinesIBA 03/2008 - 09/2007
2	interleukin-21 (interleukin 21)IBA 03/2008 - 09/2007
2	Heparin (Liquaemin)FDA LinkGeneric 10/2005 - 07/2005
2	CoagulantsIBA 10/2005 - 07/2005
1	RNA (Ribonucleic Acid)IBA 01/2020
1	human ERBB2 proteinIBA 01/2020
1	AlbuminsIBA 01/2020
1	BuffersIBA 01/2020
1	Cisplatin (Platino)FDA LinkGeneric 01/2020
1	Cell Surface ReceptorsIBA 01/2020
1	Phosphatidylinositol 3-Kinase (1 Phosphatidylinositol 3 Kinase)IBA 01/2020
1	Immune Checkpoint InhibitorsIBA 01/2019
1	epidermal growth factor receptor VIIIIBA 07/2018
1	Circulating Tumor DNAIBA 04/2018
1	Neutralizing AntibodiesIBA 11/2017
1	Neuregulin-1 (Neuregulin 1)IBA 11/2017
1	Messenger RNA (mRNA)IBA 11/2017
1	Immunoglobulin G (IgG)IBA 10/2017
1	pertuzumabIBA 03/2015
1	Caspase 3 (Caspase-3)IBA 10/2013
1	InterleukinsIBA 09/2007
1	Low-Molecular-Weight Heparin (Heparin, Low Molecular Weight)IBA 07/2005
1	Tinzaparin (Innohep)FDA Link 07/2005
1	Cyclosporine (Ciclosporin)FDA LinkGeneric 02/2003
1	Prednisolone (Predate)FDA LinkGeneric 02/2003
1	Indomethacin (Indometacin)FDA LinkGeneric 02/2003
1	flavone acetic acidIBA 05/2002
1	Hydralazine (Apresoline)FDA LinkGeneric 05/2002
1	Niacinamide (Nicotinamide)FDA LinkGeneric 05/2002
1	vadimezanIBA 05/2002
1	fosbretabulin (combretastatin A4)IBA 05/2002
1	Thrombospondin 1IBA 02/2002
1	Complementary DNA (cDNA)IBA 02/2002
1	ThrombospondinsIBA 02/2002

Therapy/Procedure

17	Therapeutics 01/2020 - 02/2002
3	Aftercare (After-Treatment) 01/2020 - 05/2002
2	Radiotherapy 02/2016 - 12/2013
2	Lasers (Laser) 05/2002 - 02/2002
1	Immunotherapy 01/2019